Table 2 Characteristics of the intervention:
Reference | Triple-H components | Composition | Complications | |||
|---|---|---|---|---|---|---|
| Â | type | Prophylactic/Therapeutic | Intervention group | Control group | Intracranial Int/ no Int | Systemic Int/ no Int |
Ekelund, 2002 [18] | isovolemic hemodilution or hypervolemic hemodilution | Therapeutic | -Isovolemic: Venasection with simultaneous infusion of 70% dextran and 4% albumin in equal volumes -Hypervolemic (after isovolemic): Autotransfusion and infusion of 70% dextran and 4% albumin | - | unknown | unknown |
Mori, 1995 [14] | hypervolemic hemodilution | Therapeutic | 500 ml human albumin solution, 500 ml low molecular dextran per day | 900 ml 10% glycerol per day | 0%/unknown | 4%/unknown |
Yamakami, 1987 [21] | hypervolemia | Prophylactic | 500 ml 5% albumin in 30 minutes | - | unknown | unknown |
Lennihan, 2000 [13] | hypervolemia | Prophylactic | 250 ml 5% albumin in two hours | 80 ml 5% dextrose and 0.9% saline in one hour | 15%/17% | 7%/5% |
Tseng, 2003 [23] | hypervolemia | Therapeutic | 2 ml/kg 23.5% saline in 20 minutes | - | unknown | unknown |
Jost, 2005 [22] | hypervolemia | Therapeutic | 15 ml/kg 0.9% saline in one hour | - | unknown | unknown |
Muizelaar, 1986 [25] | hypertension | Therapeutic | -Phenylephrine (mean MAP increase of 33 mmHg) -hypervolemia with Ht around 32% | - | 0% | 0% |
Touho, 1992 [20] | hypertension | Both | Continuous infusion of dopamine 7 to 15 μg/kg/min (mean MAP increase of 22 mmHg) | - | unknown | unknown |
Darby, 1994 [24] | hypertension | Therapeutic | dopamine 6.4 to 20 μg/kg/min (mean MAP increase of 21 mmHg) | - | unknown | unknown |
Origitano, 1990 [15] | Triple-H | Prophylactic | -Venasection to Ht of 30 in increments of 150 to 250 ml every eight hours within 12 to 24 hours -infusion of 250 to 500 ml 5% albumin every six hours -dopamine or labetolol (mean MAP increase not written) | - | 0% | 9% |
Muench, 2007 [19] | Triple-H or hypertension or hypervolemic hemodilution | Prophylactic | -norepinephrine to raise MAP above 130 mmHg (mean MAP increase not written) -1,000 ml hydroxyethyl-starch and 1,000 to 3,000 ml crystalloids | - | unknown | unknown |